AzTrials
AzTrials

Type 2 DiabetesADANCT07477067

Exercise and Protein Efficiency in T2D

A study testing 12 week progressive exercise training in people with Type 2 Diabetes and Control Condition, run by University of Illinois at Urbana-Champaign at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

In this randomized controlled trial, 30 older adults (aged> 65 years; 15 with T2D, 15 controls) will participate in a 12-week progressive exercise training program. They will undergo pre- and post-testing that includes body composition measures; oral glucose tolerance testing; cardiovascular fitness and muscle… Read more about this study

Who is it for?
Ages 65 years and olderHealthy volunteers can take part
Conditions the study is for
Type 2 Diabetes, Control Condition
What is being tested?
12 week progressive exercise training
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteUnited States
Study dates
9 Feb 2026to 1 Jul 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • Healthy volunteers accepted
  • Older adult

Who may be able to join

  • At least 65 years old
  • Body mass index: 25-40 kg/m^2
  • Female: Waist to hip ratio >0.8
  • Male: Waist to hip ratio >1.0
  • Free from structured exercise during the prior 6 months (mo) weight stable for the prior 6 months
  • T2D group:
Show all 9Show fewer
  • -Diagnosed by a physician with elevated glycosylated hemoglobin (HbA1c) >6.5%
  • Control group:
  • -Normoglycemic with HbA1c levels not exceeding 5.6% and fasting blood glucose levels below or equal to 99 mg/dL (5.5mmol)

Who cannot join

  • Uncontrolled diabetes (evidence of HbA1c > 10%, prescription of insulin)
  • Diagnoses of diabetic neuropathy or failing diabetic neuropathy screening
  • Statins
  • Peripheral edema Consumption of ergogenic-levels of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation.
  • Untreated hypothyroidism, epilepsy, medications that affect vasoactivity, possibility of pregnancy, and any neurological, cardiovascular, or musculoskeletal disease that precludes exercise testing.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Nicholas Burd (Professor), PhD contact

2172440970

naburd@illinois.edu

Gena Irwin (Research Assistant), M.S contact

3608883281

genai2@illinois.edu

United States1 site, 1 recruiting
  • Freer Hall - University of Illinois

    Urbana, Illinois, 61801

    Nicholas Burd (Professor), PhD, 2172440970, naburd@illinois.edu

    Recruiting

Other trials in United States

About this study

Official title: Exercise Impact on Dietary Protein Efficiency in Older Adults With Type 2 Diabetes

In this randomized controlled trial, 30 older adults (aged> 65 years; 15 with T2D, 15 controls) will participate in a 12-week progressive exercise training program. They will undergo pre- and post-testing that includes body composition measures; oral glucose tolerance testing; cardiovascular fitness and muscle performance testing; dietary protein efficiency assessed using the indicator amino acid oxidation (IAAO) method; and a gut microbiota trial. The dietary protein efficiency trial will include repeated ingestion of crystallized amino acids (drink) containing stable isotopes, urine samples, and breath samples. The gut microbiome trial will consist of a single ingestion of a Mediterranean-based modeled meal enriched with 13C-phenylalanine (in the drink) and repeated blood draws. Participants will also be asked to give a fecal sample after the gut microbiome trial.

Read the detailed description
  1. Enrollment, Informed Consent, and Screening Questionnaires: Prior to study enrollment, participants will be asked to read a digital copy of an informed consent document provided using the e-Consent framework through the Research Electronic Data Capture (REDCap) system. Should participants have any questions about the study after reading the document, they will be encouraged to contact the research team prior to providing informed consent. Upon providing informed consent, participants will receive an email containing questionnaires designed to assess study eligibility via REDCap. Specifically, participants will be asked to complete a health and medical history questionnaire, physical activity readiness questionnaire (PARQ), International Physical Activity Questionnaire Long Form (IPAQ), and Godin-Shephard Leisure-Time Physical Activity Questionnaire (LTPAQ). Information from the questionnaires will be used to assess exclusion criteria, and the IPAQ will be used to assess baseline habitual activity level. Upon completion of these questionnaires, the research team will review the responses and determine eligibility.
  2. Preliminary Testing Day 1:

2.1 Preparation: Participants will arrive for the preliminary testing session after an overnight fast (~10 h no caloric foods/beverages consumed) and having refrained from exercise for the 72 h prior.

3.2 Cardiorespiratory fitness assessment: Peak aerobic capacity and maximum heart rate (HR) will be estimated using a submaximal graded stationary bicycle exercise test. Briefly, participants will pedal for 3 minutes at a resistance of 0kg, maintaining a cadence of 50 as a warm-up. Then, the investigators will have the participant pedal for 3-4 minutes, or until a steady state is reached, at 0.5kg, maintaining the same cadence. Resistance is increased every 3-4 minutes until the participant reaches 85% of age-predicted maximal heart rate (220-age).

3.3 Muscle Performance (1RM and power Testing): maximum strength will be assessed using a 10-repetition max (10-RM) on a leg extension, leg press, leg curl, chest press, shoulder press, seated pulldown, and seated row machines. Following a 5-minute warm-up on a stationary bike at a self-selected resistance and speed, participants will perform a set of 8-10 reps at around 50% of what they think they can lift 10 times. 1-2 minutes of rest will be given between each try. The next set will be around 90% of what the participant believes they can lift ten times. investigators will gradually increase the weight by 2.5-5.0% at a time until the participant can no longer lift it. A two-minute rest will be provided between the maximum number of attempts and between exercises.

3.3.5 The HUMAC NORM Isokinetic Dynamometer (CSMi, Stoughton, Massachusetts) will be used to assess peak torque, average workload, and average power in concentric tests and maximal voluntary contraction (MVC). Each participant will be seated upright, with the knee bent. The shank of the dominant leg will be secured to a padded, rigid metal bar using a Velcro strap. With standardized verbal encouragement, participants will perform brief maximal voluntary isometric contractions (MVC), separated by at least 60 seconds of rest, to determine maximal knee extension torque. Maximal power of the knee extensor muscles will be obtained at several test velocities using 2 sets of 4 maximal isokinetic knee extensions, including at a velocity of 60 deg/s. Strong verbal encouragement will be provided to kick as hard and as fast as possible throughout the full range of motion for each velocity. Participants will rest for at least 60 seconds after each set of 4 contractions to minimize muscle fatigue during the power assessment.

  1. Preliminary testing day 3: Dietary Efficiency trial 4.1 Preparations: 3 days prior to the trial, participants will receive 3 days' worth of standardized meals and be instructed to prepare meals based on the manufacturer's instructions. Participants will arrive for the preliminary testing session after an overnight fast (~10 hours, no caloric foods/beverages consumed) and after refraining from exercise for the 72 hours prior.

5.2 Blood Collection: An intravenous catheter will be placed in a hand or arm vein for repeat blood sampling. Blood samples will be collected at 10 time points (-30, 0, 30, 60, 90, 120, 150, 180, 240, and 300 minutes) during each gut microbiome trial (pre- and post-training).

5.3 Mediterranean-based modeled meal: At time point 0, participants will be asked to ingest ~20g of protein enriched with L-[ring- 13C6] Phenylalanine to ~30 MPE. The amino acid and fat composition of this meal will be modeled based on ~3.05 oz of salmon filet.

  1. Fecal Collection A fecal sample collection kit will be provided to participants, and they will be asked to collect the first stool produced after the postprandial gut microbiota tracer trial (5.0). Participants will be asked to adhere to a three-day controlled diet prior to each of 2 fecal collections (1x pre-testing, 1x post-testing), and samples will be delivered to the lab at their next study visit.

7.0 Exercise Training: 7.1 Strength Training: On strength training days, participants will warm up on a stationary bike for 5 minutes before each training session. The training session will consist of 1-3 sets on the leg press, leg extension, and leg curl machines. In addition, participants will be asked to perform upper-body exercises on guided machines (seated chest press, seated shoulder press, seated row) on alternating training days. All sessions will be separated by 2-3 days. Training intensity will be progressive and based on individual comfort levels. During the first week of training (week 0), the training intensity will be gradually increased from ~60% 1 Repetition Max (1RM) (10-15 repetitions) to ~70% 1RM (10-12 repetitions).

7.2 Endurance training: For aerobic-based training, supervised exercise sessions will occur on a stationary bike. Exercise intensity will be controlled by heart rate (HR) and Rate of Perceived Exertion (RPE) using Borg's original scale (6-20 points). Exercise intensity will be progressive: weeks 1-3 will be 50-60% HR for 30 minutes; weeks 4-6, 50-60% for 40 minutes; weeks 7-9, 60-70% for 50 minutes; weeks 10-12, 60-70% for 60 minutes.

  1. Psychological Evaluation During each in-person exercise day, participants will be evaluated using several psychological well-being questionnaires. The International Personality Item Pool (IPIP-50) is a 50-item assessment of the Five-Factor Model (Openness to Experience, Conscientiousness, Extraversion, Agreeableness, and Neuroticism/Emotional Stability). Additionally, the PRETIE-Q is a 16-item questionnaire designed to assess personal preferences for exercise intensity and perceived tolerance for it. The Dispositional Resilience Scale (DRS-15) will be used to assess participants' resilience, and the Hospital Anxiety and Depression Scale (HADS), a 14-item instrument used to assess the severity of anxiety and depressive symptoms in the past 7 days. The option to do these electronically or on paper will be given.
Being tested
12 week progressive exercise training
Keywords
Type 2 Diabetes, Obesity, Exercise Intervention, Protein Metabolism
Medical subject headings
Diabetes Mellitus, Type 2, Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 12 week progressive exercise trainingOther

    Also called 12-week progressive training

    moderate - to - vigorous aerobic and strength-based exercise training will be performed 2-3 times per week for 12 weeks.

    Strength Training consists of a 5-minute warm-up on a stationary bike, followed by 1-3 sets on the leg press, leg extension, and leg curl machines. In addition, participants will preform upper body exercises on guided motion machines (seated chest press, shoulder press, seated rows) on alternate training days. Training intensity will gradually increase on each participants comfort level.

    Endurance training will be performed on a stationary bike. Exercise intensity will be controlled by heart rate and rate of perceived exertion (RPE) using the Borg's original scale (6-20 points). Weeks 1--3 will be at 50-60% of max heart rate for 30 minutes; weeks 4-6 will be at 50-60% of max heart rate for 40 minutes; weeks 7-9 will be 60-70% of max heart rate for 50 minutes; and weeks 10-12 will be at 60-70% of max heart rate for 60 minutes.

Study groups in NCT07477067
Study groupRoleWhat they receive
Non-DiabeticActive comparatorNon-diabetic control group. Will be assigned to all pre-/post-testing and complete the 12-week intervention period.
Receives: Other: 12 week progressive exercise training
Diabetic groupExperimentalDiagnosed diabetic group. Will complete all pre- and post-testing and the 12-week intervention period.
Receives: Other: 12 week progressive exercise training

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Define how exercise modifies protein efficiency in T2D

    Define how exercise modifies protein efficiency by assessing whole-body net protein balance via amino acid oxidation rates in response to protein intake of 1.0 g protein/kg/d. We expect to observe elevated baseline (pre-training) rates of oxidative excretion in aging T2D compared with CON. Following 12 weeks of exercise, both groups will improve their whole-body net protein balance, (indicative of lower oxidation rates), but the largest effects will be observed in the T2D vs CON group

    Measured: From enrollment to end of 12-week intervention

Secondary outcomes (1)
  1. Impact of training on gut microbiota on derived metabolites

    Exercise training in older adults with T2D shifts aromatic amino acid (ArAA) metabolism toward beneficial aryl-lactates (e.g., PLA) and away from harmful aryl-acetates (e.g., PAG). Pre- and post-exercise intervention conversion of phenylalanine will be assessed with acute labeled 13C6 Phe ingestion. Downstream labeled Phe metabolites (ng/mL) will be quantified in blood serum over 5 hours post-labeled Phe intake.

    Measured: from pretesting to post testing following a 12-week exercise intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Mar 2026
  2. Study start9 Feb 2026
  3. Primary completion30 Jun 2027 (estimated)
  4. Study completion1 Jul 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
non-Randomized Control Design
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07477067
Sponsor's protocol ID
IRB25-0851
Other IDs
7-25-ICTSAD-418
Acronym
ADA
Status last verified
Feb 2026
First submitted
1 Dec 2025
Last updated
29 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Because it is not intended for publication in any ICMJE journal.

Questions about this trial

What is this clinical trial studying?

A study testing 12 week progressive exercise training in people with Type 2 Diabetes and Control Condition, run by University of Illinois at Urbana-Champaign at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Nicholas Burd (Professor), PhD (2172440970, naburd@illinois.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Define how exercise modifies protein efficiency in T2D (time frame: From enrollment to end of 12-week intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Exercise and Protein Efficiency in T2D (NCT07477067) | AzTrials